11/19/24 16:39 | 11/15/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Marshall Robert J. Jr. | MA | O | CFO,Trea | S | -812 | 81.20 | 0 | -10 | -9 | 103 | D | | | | | | | | | | | | | | |
11/18/24 17:36 | 11/14/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Blanchfield Paul | MA | O | P | S | -159 | 79.65 | 0 | -2 | -2 | 97 | D | | | | | | | | | | | | | | |
11/12/24 17:41 | 11/8/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Heino Mary Anne | MA | D | | S | -1,001 | 87.16 | 0 | -11 | -2 | 611 | D | | | | | | | | | | | | | | |
10/11/24 17:23 | 10/11/24 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Diaz Paul J | UT | DO | P,CEO | S | -344 | 22.93 | 0 | -15 | -2 | 962 | D | | | | | | | | | | | | | | |
10/4/24 17:29 | 10/2/24 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Dube Michael P | MA | O | VP,Chief | S | -38 | 19.01 | 0 | -2 | -4 | 47 | D | | | | | | | | | | | | | | |
9/12/24 16:11 | 9/11/24 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Diaz Paul J | UT | DO | P,CEO | S | -401 | 26.72 | 0 | -15 | -2 | 977 | D | | | | | | | | | | | | | | |
9/12/24 16:09 | 9/11/24 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Muzzey Dale | UT | O | Chief Sc | S | -55 | 26.17 | 0 | -2 | -2 | 108 | D | | | | | | | | | | | | | | |
9/9/24 17:48 | 9/9/24 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Dreismann Heinrich | UT | D | | S | -271 | 27.05 | 0 | -10 | -8 | 122 | D | | | | | | | | | | | | | | |
9/4/24 21:13 | 2/2/24 | IONS | Ionis Pharmaceuticals Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Hougen Elizabeth L | CA | O | EVP,Fina | S.a | -107 | 49.54 | 0 | -2 | -2 | 93 | D | | | | | | | | | | | | | | |
9/4/24 19:38 | 9/3/24 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Reitan Colleen F | UT | D | | S | -1,286 | 27.95 | 0 | -46 | -52 | 43 | D | | | | | | | | | | | | | | |
8/23/24 16:30 | 8/21/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Thrall James H | MA | D | | S | -99 | 98.52 | 0 | -1 | -3 | 34 | D | | | | | | | | | | | | | | |
8/23/24 16:16 | 8/21/24 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Ancona Margaret | UT | O | SVP,Chie | S | -321 | 27.82 | 0 | -12 | -13 | 79 | D | | | | | | | | | | | | | | |
8/20/24 16:38 | 8/19/24 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Kumar Rashmi | UT | D | | S | -210 | 28.01 | 0 | -8 | -9 | 77 | D | | | | | | | | | | | | | | |
8/16/24 16:30 | 8/14/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Niedzwiecki Daniel | MA | O | See Rema | S | -244 | 97.54 | 0 | -3 | -3 | 78 | D | | | | | | | | | | | | | | |
8/14/24 16:56 | 8/12/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Ber Gerard | MA | D | | S | -1,495 | 96.48 | 0 | -16 | -42 | 21 | D | | | | | | | | | | | | | | |
8/12/24 17:09 | 8/8/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Blanchfield Paul | MA | O | P | S | -193 | 96.39 | 0 | -2 | -2 | 99 | D | | | | | | | | | | | | | | |
8/6/24 16:30 | 8/2/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Heino Mary Anne | MA | D | | S | -1,001 | 95.50 | 0 | -10 | -2 | 623 | D | | | | | | | | | | | | | | |
7/17/24 16:30 | 7/15/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S.m | -266 | 124.67 | 0 | -2 | -3 | 60 | D | | | | | | | | | | | | | | |
7/12/24 16:30 | 7/10/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Pruden Gary J | MA | D | | S | -1,191 | 95.04 | 0 | -13 | -35 | 23 | I | | | | | | | | | | | | | | |
7/3/24 13:15 | 7/1/24 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Clark Eliana | MA | O | EVP,Chie | S | -9 | 22.93 | 0 | 0 | -1 | 71 | D | | | | | | | | | | | | | | |
6/20/24 17:00 | 6/17/24 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Verwiel Frank | MA | D | | S | -38 | 25.00 | 0 | -2 | -8 | 18 | D | | | | | | | | | | | | | | |
6/18/24 16:05 | 6/14/24 | CLDX | Celldex Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Martin Samuel Bates | NJ | O | SVP,CFO | S.d | -608 | 35.42 | 0 | -17 | -38 | 28 | D | | | | | | | | | | | | | | |
6/18/24 16:04 | 6/14/24 | CLDX | Celldex Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Crowley Elizabeth | NJ | O | SVP,CPDO | S.d | -1,046 | 34.87 | 0 | -30 | -77 | 9 | D | | | | | | | | | | | | | | |
6/17/24 16:30 | 6/13/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S | -27 | 79.77 | 0 | 0 | -1 | 63 | D | | | | | | | | | | | | | | |
6/11/24 16:02 | 6/7/24 | CLDX | Celldex Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Crowley Elizabeth | NJ | O | SVP,CPDO | S.d | -526 | 35.06 | 0 | -15 | -62 | 9 | D | | | | | | | | | | | | | | |
6/11/24 16:01 | 6/7/24 | CLDX | Celldex Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Young Diane C. | NJ | O | SVP,Chie | S | -1,587 | 35.26 | 0 | -45 | -96 | 2 | D | | | | | | | | | | | | | | |
6/5/24 16:06 | 6/3/24 | CLDX | Celldex Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Heath-Chiozzi Margo | NJ | O | SVP of R | S.d | -1,964 | 33.65 | 0 | -58 | -81 | 13 | D | | | | | | | | | | | | | | |
6/5/24 16:05 | 6/3/24 | CLDX | Celldex Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Wright Richard M. | NJ | O | SVP,CCO | S.d | -1,579 | 33.72 | 0 | -47 | -69 | 21 | D | | | | | | | | | | | | | | |
6/5/24 16:04 | 6/3/24 | CLDX | Celldex Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Jimenez Freddy A. | NJ | O | SVP,GC | S.d | -269 | 33.60 | 0 | -8 | -24 | 26 | D | | | | | | | | | | | | | | |
6/4/24 17:57 | 6/3/24 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Spiegelman Daniel K | UT | D | | S.m | -167 | 22.05 | 0 | -8 | -19 | 33 | D | | | | | | | | | | | | | | |
6/3/24 16:30 | 5/30/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Niedzwiecki Daniel | MA | O | See Rema | S | -1,028 | 79.86 | 0 | -13 | -14 | 80 | D | | | | | | | | | | | | | | |
6/3/24 16:06 | 5/30/24 | CLDX | Celldex Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Heath-Chiozzi Margo | NJ | O | SVP of R | S.d | -1,319 | 34.07 | 0 | -39 | -85 | 7 | D | | | | | | | | | | | | | | |
6/3/24 16:05 | 5/30/24 | CLDX | Celldex Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Martin Samuel Bates | NJ | O | SVP,CFO | S.d | -1,192 | 34.05 | 0 | -35 | -58 | 25 | D | | | | | | | | | | | | | | |
6/3/24 16:04 | 5/30/24 | CLDX | Celldex Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Cavanaugh Sarah | NJ | O | SVP of C | S.d | -703 | 33.73 | 0 | -21 | -92 | 2 | D | | | | | | | | | | | | | | |
6/3/24 16:04 | 5/30/24 | CLDX | Celldex Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Crowley Elizabeth | NJ | O | SVP,CPDO | S.d | -1,298 | 33.64 | 0 | -39 | -81 | 9 | D | | | | | | | | | | | | | | |
5/30/24 16:34 | 5/28/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Maeusli Heinz Christoph | MA | D | | S.d | -1,455 | 79.19 | 0 | -18 | -44 | 23 | D | | | | | | | | | | | | | | |
5/30/24 16:32 | 5/28/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | McHugh Julie | MA | D | | S | -196 | 78.50 | 0 | -3 | -8 | 29 | D | | | | | | | | | | | | | | |
5/20/24 17:00 | 5/17/24 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Claflin Bruce L. | ME | D | | S | -108 | 540.80 | 0 | 0 | -10 | 2 | D | | | | | | | | | | | | | | |
5/15/24 17:49 | 5/13/24 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Diaz Paul J | UT | DO | P,CEO | S.m | -5,729 | 25.14 | 0 | -228 | -18 | 1,066 | D | | | | | | | | | | | | | | |
5/15/24 17:48 | 5/13/24 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Newcomer Lee Nisley | UT | D | | S | -157 | 25.30 | 0 | -6 | -9 | 67 | D | | | | | | | | | | | | | | |
5/15/24 17:09 | 5/13/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S | -26 | 76.89 | 0 | 0 | -1 | 63 | D | | | | | | | | | | | | | | |
4/17/24 16:30 | 4/15/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S | -21 | 61.24 | 0 | 0 | -1 | 63 | D | | | | | | | | | | | | | | |
3/19/24 16:30 | 3/15/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Marshall Robert J. Jr. | MA | O | CFO,Trea | S | -1,200 | 60.00 | 0 | -20 | -15 | 114 | D | | | | | | | | | | | | | | |
3/15/24 16:30 | 3/13/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S | -21 | 60.48 | 0 | 0 | -1 | 63 | D | | | | | | | | | | | | | | |
3/11/24 16:30 | 3/7/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Blanchfield Paul | MA | O | P | S | -1,117 | 61.96 | 0 | -18 | -15 | 103 | D | | | | | | | | | | | | | | |
3/7/24 17:00 | 3/6/24 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Polewaczyk James F | ME | O | EVP | S.d | -4,526 | 558.44 | 0 | -8 | -43 | 11 | D | | | | | | | | | | | | | | |
3/7/24 17:00 | 3/5/24 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Vandebroek Sophie V. | ME | D | | S.d | -790 | 562.98 | 0 | -1 | -13 | 9 | D | | | | | | | | | | | | | | |
3/7/24 16:30 | 3/5/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leno Sam R | MA | D | | S.dm | -262 | 64.06 | 0 | -4 | -7 | 58 | D | | | | | | | | | | | | | | |
3/6/24 17:15 | 3/4/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leno Sam R | MA | D | | S.d | -1,465 | 65.42 | 0 | -22 | -28 | 58 | D | | | | | | | | | | | | | | |
3/5/24 20:28 | 3/4/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Heino Mary Anne | MA | D | | S | -6,130 | 65.31 | 0 | -94 | -13 | 631 | D | | | | | | | | | | | | | | |
3/5/24 16:10 | 3/4/24 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Basta James | MA | O | EVP,GC | S.d | -76 | 32.99 | 0 | -2 | -3 | 82 | D | | | | | | | | | | | | | | |
3/5/24 16:10 | 3/4/24 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Clark Eliana | MA | O | EVP,Chie | S.d | -20 | 32.99 | 0 | -1 | -1 | 71 | D | | | | | | | | | | | | | | |
2/15/24 16:30 | 2/13/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S | -19 | 55.31 | 0 | 0 | -1 | 58 | D | | | | | | | | | | | | | | |
2/9/24 17:03 | 2/8/24 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Fennell George | ME | O | SVP,Chie | S.d | -4,705 | 573.87 | 0 | -8 | -55 | 7 | D | | | | | | | | | | | | | | |
2/9/24 17:01 | 2/7/24 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | McKeon Brian P | ME | O | EVP,CFO, | S.d | -13,296 | 570.01 | 0 | -23 | -33 | 48 | D | | | | | | | | | | | | | | |
2/9/24 17:00 | 2/7/24 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Mazelsky Jonathan Jay | ME | DO | P,CEO | S.d | -6,871 | 572.61 | 0 | -12 | -13 | 79 | D | | | | | | | | | | | | | | |
2/2/24 19:55 | 2/2/24 | IONS | Ionis Pharmaceuticals Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Hougen Elizabeth L | CA | O | EVP,Fina | S | -105 | 49.54 | 0 | -2 | -2 | 93 | D | | | | | | | | | | | | | | |
1/18/24 17:48 | 1/17/24 | IONS | Ionis Pharmaceuticals Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Hougen Elizabeth L | CA | O | EVP,Fina | S.d | -438 | 50.42 | 0 | -9 | -9 | 91 | D | | | | | | | | | | | | | | |
1/18/24 16:30 | 1/16/24 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S | -19 | 56.01 | 0 | 0 | -1 | 59 | D | | | | | | | | | | | | | | |
1/10/24 16:15 | 1/8/24 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sepp-Lorenzino Laura | MA | O | EVP,Chie | S | -66 | 28.87 | 0 | -2 | -5 | 44 | D | | | | | | | | | | | | | | |
1/5/24 16:51 | 1/3/24 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | S | -566 | 29.46 | 0 | -19 | -2 | 905 | D | | | | | | | | | | | | | | |
1/5/24 16:50 | 1/3/24 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Lebwohl David | MA | O | EVP,Chie | S | -172 | 29.46 | 0 | -6 | -10 | 54 | D | | | | | | | | | | | | | | |
1/5/24 16:50 | 1/3/24 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sepp-Lorenzino Laura | MA | O | EVP,Chie | S | -163 | 29.46 | 0 | -6 | -11 | 46 | D | | | | | | | | | | | | | | |
1/5/24 16:49 | 1/3/24 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Goddard Glenn | MA | O | EVP,CFO | S | -158 | 29.46 | 0 | -5 | -12 | 41 | D | | | | | | | | | | | | | | |
1/5/24 16:46 | 1/3/24 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Hicks Derek | MA | O | EVP,Chie | S | -114 | 29.46 | 0 | -4 | -9 | 37 | D | | | | | | | | | | | | | | |
1/5/24 16:45 | 1/3/24 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Basta James | MA | O | EVP,GC | S | -112 | 29.46 | 0 | -4 | -7 | 51 | D | | | | | | | | | | | | | | |
1/5/24 16:44 | 1/3/24 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Clark Eliana | MA | O | EVP,Chie | S | -136 | 29.50 | 0 | -5 | -10 | 41 | D | | | | | | | | | | | | | | |
1/3/24 10:41 | 1/2/24 | VNRX | Volitionrx Ltd | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Eight Corp Ltd | Y8 | T | | S | -18 | 0.9000 | 0 | -20 | 0 | 12,005 | I | | | | | | | | | | | | | | |
12/20/23 10:31 | 12/15/23 | VNRX | Volitionrx Ltd | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Eight Corp Ltd | Y8 | T | | S | -15 | 0.7500 | 0 | -20 | 0 | 12,025 | I | | | | | | | | | | | | | | |
12/19/23 17:00 | 12/15/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Marshall Robert J. Jr. | MA | O | CFO,Trea | S | -782 | 78.24 | 0 | -10 | -9 | 103 | D | | | | | | | | | | | | | | |
12/15/23 16:30 | 12/13/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S | -26 | 75.62 | 0 | 0 | -1 | 59 | D | | | | | | | | | | | | | | |
12/8/23 17:28 | 12/6/23 | AWH | Aspira Women'S Health Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Merchant Minh Hoang | TX | O | Secretar | S | -3 | 3.37 | 0 | -1 | -4 | 27 | I | | | | | | | | | | | | | | |
12/8/23 17:00 | 12/7/23 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Polewaczyk James F | ME | O | EVP | S.d | -6,072 | 521.79 | 0 | -12 | -54 | 10 | D | | | | | | | | | | | | | | |
12/6/23 17:01 | 12/4/23 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Mazelsky Jonathan Jay | ME | DO | P,CEO | S.d | -3,657 | 513.05 | 0 | -7 | -8 | 79 | D | | | | | | | | | | | | | | |
12/5/23 16:19 | 12/1/23 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Riggsbee Richard Bryan | UT | O | CFO | S | -573 | 19.09 | 0 | -30 | -9 | 292 | D | | | | | | | | | | | | | | |
11/20/23 16:30 | 11/16/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Blanchfield Paul | MA | O | P | S | -102 | 67.96 | 0 | -2 | -2 | 89 | D | | | | | | | | | | | | | | |
11/15/23 16:32 | 11/13/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Heino Mary Anne | MA | DO | CEO | S | -751 | 63.72 | 0 | -12 | -2 | 697 | D | | | | | | | | | | | | | | |
11/15/23 16:30 | 11/13/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S | -22 | 63.57 | 0 | 0 | -1 | 59 | D | | | | | | | | | | | | | | |
11/3/23 17:12 | 11/1/23 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Riggsbee Richard Bryan | UT | O | CFO | S | -471 | 15.69 | 0 | -30 | -9 | 322 | D | | | | | | | | | | | | | | |
11/2/23 16:42 | 10/31/23 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Bhanji Muna | MA | D | | S | -6 | 23.90 | 0 | 0 | -2 | 12 | D | | | | | | | | | | | | | | |
10/17/23 10:06 | 10/13/23 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Lilly Jason Warren | MI | O | VP | S | -5 | 15.10 | 0 | 0 | -1 | 27 | D | | | | | | | | | | | | | | |
10/13/23 17:03 | 6/2/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Baylor-Henry Minnie | MA | D | | S | -1 | 86.22 | 0 | 0 | -27 | 0 | I | | | | | | | | | | | | | | |
10/12/23 11:54 | 10/11/23 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Boehm William T | | D | | S | -40 | 15.61 | 0 | -3 | -10 | 25 | D | | | | | | | | | | | | | | |
10/12/23 11:25 | 10/11/23 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Lilly Jason Warren | MI | O | VP | S | -30 | 15.69 | 0 | -2 | -7 | 26 | D | | | | | | | | | | | | | | |
9/19/23 16:30 | 9/15/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Niedzwiecki Daniel | MA | O | See Rema | S.d | -189 | 66.43 | 0 | -3 | -4 | 66 | D | | | | | | | | | | | | | | |
9/5/23 17:01 | 8/31/23 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Mazelsky Jonathan Jay | ME | DO | P,CEO | S.d | -6,873 | 512.01 | 0 | -13 | -16 | 73 | D | | | | | | | | | | | | | | |
8/31/23 17:17 | 8/29/23 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Polewaczyk James F | ME | O | EVP | S.d | -11,696 | 510.56 | 0 | -23 | -70 | 10 | D | | | | | | | | | | | | | | |
8/23/23 16:30 | 8/21/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Blanchfield Paul | MA | O | P | S | -27 | 66.10 | 0 | 0 | 0 | 90 | D | | | | | | | | | | | | | | |
8/22/23 16:30 | 8/18/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Blanchfield Paul | MA | O | P | S | -98 | 65.19 | 0 | -2 | -2 | 90 | D | | | | | | | | | | | | | | |
8/22/23 10:57 | 8/18/23 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Boehm William T | | D | | S.d | -34 | 22.59 | 0 | -2 | -6 | 25 | D | | | | | | | | | | | | | | |
8/17/23 19:37 | 8/15/23 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Ayers Jonathan W | ME | D | | S | 0 | 0.00 | 0 | 0 | 0 | 596 | D | | | | | | | | | | | | | | |
8/17/23 16:30 | 8/15/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Marshall Robert J. Jr. | MA | O | CFO,Trea | S | -685 | 68.52 | 0 | -10 | -8 | 108 | D | | | | | | | | | | | | | | |
8/15/23 17:35 | 8/11/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Heino Mary Anne | MA | DO | CEO | S | -751 | 68.58 | 0 | -11 | -2 | 708 | D | | | | | | | | | | | | | | |
8/15/23 16:54 | 8/11/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Niedzwiecki Daniel | MA | O | See Rema | S | -292 | 67.93 | 0 | -4 | -6 | 66 | D | | | | | | | | | | | | | | |
8/7/23 17:04 | 8/3/23 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Lane Michael | ME | O | EVP | S.d | -8,174 | 510.00 | 0 | -16 | -78 | 5 | D | | | | | | | | | | | | | | |
8/2/23 17:19 | 7/31/23 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Bhanji Muna | MA | D | | S | -11 | 42.33 | 0 | 0 | -2 | 12 | D | | | | | | | | | | | | | | |
7/21/23 16:30 | 7/19/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S | -159 | 90.87 | 0 | -2 | -3 | 60 | D | | | | | | | | | | | | | | |
7/10/23 17:21 | 7/6/23 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Bhanji Muna | MA | D | | S | -73 | 39.30 | 0 | -2 | -13 | 13 | D | | | | | | | | | | | | | | |
7/6/23 15:34 | 7/3/23 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Clark Eliana | MA | O | EVP,Chie | S | -15 | 40.51 | 0 | 0 | -1 | 45 | D | | | | | | | | | | | | | | |
6/22/23 17:52 | 6/20/23 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Clark Eliana | MA | O | EVP,Chie | S.d | -225 | 45.00 | 0 | -5 | -10 | 45 | D | | | | | | | | | | | | | | |
6/14/23 16:55 | 6/13/23 | TKNO | Alpha Teknova, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Hood Lisa | CA | O | Chief Pe | S | -43 | 3.80 | 0 | -11 | -25 | 34 | D | | | | | | | | | | | | | | |
6/2/23 18:15 | 6/2/23 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Spiegelman Daniel K | UT | D | | S | -199 | 23.01 | 0 | -9 | -18 | 40 | D | | | | | | | | | | | | | | |
5/22/23 18:47 | 5/18/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Blanchfield Paul | MA | O | P | S | -147 | 97.93 | 0 | -2 | -2 | 92 | D | | | | | | | | | | | | | | |
5/22/23 17:00 | 5/18/23 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Ayers Jonathan W | ME | D | | S.dm | -9,806 | 490.29 | 0 | -20 | -3 | 597 | D | | | | | | | | | | | | | | |
5/17/23 18:17 | 5/17/23 | TKNO | Alpha Teknova, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Hood Lisa | CA | O | Chief Pe | S | -6 | 2.04 | 0 | -3 | -6 | 45 | D | | | | | | | | | | | | | | |
5/17/23 16:31 | 5/15/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S | -38 | 99.36 | 0 | 0 | -1 | 62 | D | | | | | | | | | | | | | | |
5/17/23 16:30 | 5/15/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Marshall Robert J. Jr. | MA | O | CFO,Trea | S | -994 | 99.36 | 0 | -10 | -8 | 118 | D | | | | | | | | | | | | | | |
5/15/23 18:34 | 5/11/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Niedzwiecki Daniel | MA | O | See Rema | S | -604 | 98.82 | 0 | -6 | -8 | 72 | D | | | | | | | | | | | | | | |
5/8/23 17:01 | 5/5/23 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Lane Michael | ME | O | EVP | S | -484 | 484.00 | 0 | -1 | -18 | 5 | D | | | | | | | | | | | | | | |
5/5/23 18:01 | 5/4/23 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Vandebroek Sophie V. | ME | D | | S.d | -1,026 | 469.02 | 0 | -2 | -19 | 9 | M | | | | | | | | | | | | | | |
4/19/23 17:33 | 4/17/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S | -34 | 88.67 | 0 | 0 | -1 | 62 | D | | | | | | | | | | | | | | |
4/19/23 17:32 | 4/17/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Montagut Etienne | MA | O | Chief Bu | S | -188 | 88.67 | 0 | -2 | -3 | 67 | D | | | | | | | | | | | | | | |
4/5/23 16:30 | 4/3/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Montagut Etienne | MA | O | Chief Bu | S | -302 | 82.09 | 0 | -4 | -5 | 69 | D | | | | | | | | | | | | | | |
3/29/23 21:11 | 3/27/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Heino Mary Anne | MA | DO | CEO | S.ad | -3,593 | 80.77 | 0 | -44 | -6 | 719 | D | | | | | | | | | | | | | | |
3/29/23 17:51 | 3/27/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Markison Brian A | MA | D | | S | -1,078 | 81.13 | 0 | -13 | -41 | 19 | D | | | | | | | | | | | | | | |
3/29/23 17:51 | 3/27/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Heino Mary Anne | MA | DO | CEO | S.d | -3,593 | 80.77 | 0 | -44 | -6 | 719 | I | | | | | | | | | | | | | | |
3/29/23 17:51 | 3/27/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Montagut Etienne | MA | O | Chief Bu | S | -1,179 | 81.13 | 0 | -15 | -17 | 73 | D | | | | | | | | | | | | | | |
3/29/23 17:48 | 3/27/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leno Sam R | MA | D | | S.d | -566 | 80.75 | 0 | -7 | -11 | 56 | D | | | | | | | | | | | | | | |
3/28/23 17:23 | 3/27/23 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Lambert Nicole | UT | O | COO | S | -151 | 23.48 | 0 | -6 | -3 | 241 | D | | | | | | | | | | | | | | |
3/17/23 16:30 | 3/15/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S | -28 | 71.58 | 0 | 0 | -1 | 62 | D | | | | | | | | | | | | | | |
3/17/23 16:30 | 3/15/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Marshall Robert J. Jr. | MA | O | CFO,Trea | S | -358 | 71.58 | 0 | -5 | -4 | 128 | D | | | | | | | | | | | | | | |
3/13/23 18:30 | 3/3/23 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Engelson Erik T. | CA | DO | P,Chief | S.d | -657 | 1.04 | 0 | -635 | -71 | 261 | D | | | | | | | | | | | | | | |
3/13/23 17:10 | 3/3/23 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Narido Richard Clavano | CA | O | CFO | S.m | -29 | 1.00 | 0 | -29 | -27 | 78 | D | | | | | | | | | | | | | | |
3/13/23 17:09 | 3/3/23 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Collins Kevin Walter | CA | O | Chief Re | S.m | -74 | 0.6604 | 0 | -112 | -32 | 235 | D | | | | | | | | | | | | | | |
3/13/23 17:08 | 3/3/23 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Allen Anthony Joseph | CA | O | Chief Op | S | -8 | 1.00 | 0 | -8 | -6 | 137 | D | | | | | | | | | | | | | | |
3/10/23 17:08 | 3/8/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Heino Mary Anne | MA | DO | P,CEO | S | -752 | 74.70 | 0 | -10 | -1 | 719 | D | | | | | | | | | | | | | | |
3/8/23 18:47 | 3/6/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Blanchfield Paul | MA | O | COO | S.m | -580 | 72.42 | 0 | -8 | -8 | 86 | D | | | | | | | | | | | | | | |
3/8/23 18:46 | 3/6/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Marshall Robert J. Jr. | MA | O | CFO,Trea | S.m | -1,844 | 72.48 | 0 | -25 | -16 | 133 | D | | | | | | | | | | | | | | |
3/8/23 18:45 | 3/6/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Montagut Etienne | MA | O | Chief Bu | S.m | -1,284 | 72.48 | 0 | -18 | -17 | 87 | D | | | | | | | | | | | | | | |
3/8/23 18:44 | 3/6/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Niedzwiecki Daniel | MA | O | See Rema | S.m | -735 | 72.52 | 0 | -10 | -12 | 75 | D | | | | | | | | | | | | | | |
3/8/23 18:44 | 3/6/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S.m | -628 | 72.52 | 0 | -9 | -12 | 63 | D | | | | | | | | | | | | | | |
3/6/23 21:09 | 3/3/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Heino Mary Anne | MA | DO | P,CEO | S.dm | -6,882 | 73.03 | 0 | -94 | -11 | 729 | D | | | | | | | | | | | | | | |
3/3/23 17:10 | 3/2/23 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Basta James | MA | O | EVP,GC | S.d | -48 | 43.88 | 0 | -1 | -2 | 55 | D | | | | | | | | | | | | | | |
3/3/23 17:07 | 3/2/23 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Riggsbee Richard Bryan | UT | O | CFO | S | -338 | 22.55 | 0 | -15 | -4 | 338 | D | | | | | | | | | | | | | | |
3/3/23 17:04 | 3/2/23 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Lambert Nicole | UT | O | COO | S | -300 | 22.74 | 0 | -13 | -6 | 215 | D | | | | | | | | | | | | | | |
2/22/23 16:15 | 2/17/23 | QDEL | Quidelortho Corp | | Health | Diagn | In Vitro & In Vivo Diagnostic | Buechler Kenneth F | CA | D | | S.d | -729 | 90.26 | 0 | -8 | -10 | 70 | D | | | | | | | | | | | | | | |
2/21/23 12:38 | 2/16/23 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Kashmolah Ghazi | CA | O | Ex VP,Ch | S | -1 | 0.2700 | 0 | -5 | -4 | 134 | D | | | | | | | | | | | | | | |
2/17/23 17:06 | 2/16/23 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Junius Daniel M | ME | D | | S.d | -1,119 | 511.68 | 0 | -2 | -42 | 3 | D | | | | | | | | | | | | | | |
2/17/23 17:04 | 2/15/23 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Turner Kathy V | ME | O | SVP | S.dm | -515 | 510.09 | 0 | -1 | -12 | 7 | D | | | | | | | | | | | | | | |
2/17/23 16:30 | 2/15/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S | -22 | 57.52 | 0 | 0 | -1 | 60 | D | | | | | | | | | | | | | | |
2/16/23 18:56 | 2/14/23 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Turner Kathy V | ME | O | SVP | S.d | -1,009 | 504.59 | 0 | -2 | -21 | 7 | D | | | | | | | | | | | | | | |
2/13/23 17:01 | 2/9/23 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Turner Kathy V | ME | O | SVP | S.d | -505 | 505.04 | 0 | -1 | -12 | 7 | D | | | | | | | | | | | | | | |
2/7/23 17:36 | 2/6/23 | IONS | Ionis Pharmaceuticals Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Hougen Elizabeth L | CA | O | EVP,Fina | S | -84 | 40.59 | 0 | -2 | -3 | 75 | D | | | | | | | | | | | | | | |
1/23/23 16:14 | 1/20/23 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Riggsbee Richard Bryan | UT | O | CFO | S | -188 | 20.04 | 0 | -9 | -3 | 364 | D | | | | | | | | | | | | | | |
1/19/23 20:19 | 1/18/23 | IONS | Ionis Pharmaceuticals Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Hougen Elizabeth L | CA | O | EVP,Fina | S.d | -329 | 39.70 | 0 | -8 | -10 | 73 | D | | | | | | | | | | | | | | |
1/19/23 17:56 | 1/18/23 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Riggsbee Richard Bryan | UT | O | CFO | S | -12 | 20.01 | 0 | -1 | 0 | 374 | D | | | | | | | | | | | | | | |
1/19/23 16:45 | 1/17/23 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S | -20 | 52.97 | 0 | 0 | -1 | 61 | D | | | | | | | | | | | | | | |
1/6/23 17:39 | 1/4/23 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sepp-Lorenzino Laura | MA | O | EVP,Chie | S.m | -183 | 37.82 | 0 | -5 | -22 | 18 | D | | | | | | | | | | | | | | |
1/6/23 17:32 | 1/4/23 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | S | -248 | 37.21 | 0 | -7 | -1 | 825 | D | | | | | | | | | | | | | | |
1/6/23 17:29 | 1/4/23 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Hicks Derek | MA | O | EVP,Chie | S | -67 | 37.21 | 0 | -2 | -9 | 17 | D | | | | | | | | | | | | | | |
1/6/23 17:26 | 1/4/23 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Lebwohl David | MA | O | EVP,Chie | S | -96 | 37.21 | 0 | -3 | -9 | 26 | D | | | | | | | | | | | | | | |
1/6/23 17:23 | 1/4/23 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Goddard Glenn | MA | O | EVP,CFO | S | -90 | 37.21 | 0 | -2 | -14 | 15 | D | | | | | | | | | | | | | | |
1/6/23 17:21 | 7/1/22 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Clark Eliana | MA | O | EVP,Chie | S.m | -76 | 37.65 | 0 | -2 | -12 | 14 | D | | | | | | | | | | | | | | |
1/6/23 17:19 | 1/4/23 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Basta James | MA | O | EVP,GC | S | -42 | 37.21 | 0 | -1 | -5 | 20 | D | | | | | | | | | | | | | | |
12/28/22 16:05 | 12/27/22 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Riggsbee Richard Bryan | UT | O | CFO | S | -303 | 15.15 | 0 | -20 | -5 | 374 | D | | | | | | | | | | | | | | |
12/22/22 14:24 | 12/20/22 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Allen Anthony Joseph | CA | O | Chief Op | S | -1 | 0.1600 | 0 | -4 | -3 | 145 | D | | | | | | | | | | | | | | |
12/19/22 16:31 | 12/15/22 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S | -21 | 53.75 | 0 | 0 | -1 | 61 | D | | | | | | | | | | | | | | |
12/9/22 16:24 | 11/21/22 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Allen Anthony Joseph | CA | O | Chief Op | S | -11 | 0.3300 | 0 | -34 | -19 | 149 | D | | | | | | | | | | | | | | |
12/9/22 16:17 | 11/28/22 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Kashmolah Ghazi | CA | O | Ex VP,Ch | S | -3 | 0.4200 | 0 | -8 | -5 | 139 | D | | | | | | | | | | | | | | |
12/9/22 16:15 | 11/17/22 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Kashmolah Ghazi | CA | O | Ex VP,Ch | S | -12 | 0.3724 | 0 | -33 | -18 | 147 | D | | | | | | | | | | | | | | |
12/9/22 16:07 | 12/7/22 | CLDX | Celldex Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Keler Tibor | NJ | O | EVP,CSO | S.d | -623 | 36.93 | 0 | -17 | -70 | 7 | D | | | | | | | | | | | | | | |
12/7/22 16:30 | 12/5/22 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Junius Daniel M | ME | D | | S.d | -1,294 | 424.91 | 0 | -3 | -51 | 3 | D | | | | | | | | | | | | | | |
12/6/22 16:21 | 12/1/22 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Narido Richard Clavano | CA | O | Interim | S | -1 | 0.3600 | 0 | -2 | -1 | 107 | D | | | | | | | | | | | | | | |
12/5/22 17:00 | 12/1/22 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Turner Kathy V | ME | O | SVP | S.d | -1,308 | 436.00 | 0 | -3 | -30 | 7 | D | | | | | | | | | | | | | | |
11/29/22 17:43 | 11/25/22 | QTNT | Quotient Ltd | Y9 | Health | Diagn | In Vitro & In Vivo Diagnostic | Buckle Isabelle | V8 | D | | S.d | -1 | 0.8800 | 0 | -1 | -100 | 0 | D | | | | | | | | | | | | | | |
11/29/22 12:08 | 11/27/22 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Collins Kevin Walter | CA | O | Chief Re | S | -4 | 0.4200 | 0 | -10 | -3 | 347 | D | | | | | | | | | | | | | | |
11/22/22 16:35 | 11/18/22 | QTNT | Quotient Ltd | Y9 | Health | Diagn | In Vitro & In Vivo Diagnostic | Von Prondzynski Heino | Y9 | D | | S.d | -30 | 1.18 | 0 | -25 | -70 | 11 | D | | | | | | | | | | | | | | |
11/21/22 16:30 | 11/17/22 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Blanchfield Paul | MA | O | COO | S | -133 | 54.79 | 0 | -2 | -3 | 74 | D | | | | | | | | | | | | | | |
11/18/22 20:05 | 11/16/22 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Kashmolah Ghazi | CA | O | Ex VP,Ch | S | -2 | 0.3500 | 0 | -5 | -3 | 180 | D | | | | | | | | | | | | | | |
11/17/22 19:46 | 11/15/22 | TKNO | Alpha Teknova, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Hood Lisa | CA | O | Chief Pe | S.d | -11 | 5.28 | 0 | -2 | -6 | 31 | D | | | | | | | | | | | | | | |
11/17/22 16:30 | 11/15/22 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Marshall Robert J. Jr. | MA | O | CFO,Trea | S | -295 | 59.00 | 0 | -5 | -4 | 121 | D | | | | | | | | | | | | | | |
11/17/22 16:30 | 11/15/22 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S | -23 | 59.00 | 0 | 0 | -1 | 62 | D | | | | | | | | | | | | | | |
11/16/22 17:00 | 11/14/22 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Mazelsky Jonathan Jay | ME | DO | P,CEO | S.d | -4,562 | 434.47 | 0 | -11 | -13 | 71 | D | | | | | | | | | | | | | | |
11/15/22 16:30 | 11/11/22 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Niedzwiecki Daniel | MA | O | See Rema | S | -179 | 59.73 | 0 | -3 | -4 | 65 | D | | | | | | | | | | | | | | |
11/14/22 17:00 | 11/10/22 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Turner Kathy V | ME | O | SVP | S.dm | -5,921 | 426.71 | 0 | -14 | -66 | 7 | D | | | | | | | | | | | | | | |
11/10/22 16:30 | 11/8/22 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Heino Mary Anne | MA | DO | P,CEO | S | -752 | 57.21 | 0 | -13 | -2 | 673 | D | | | | | | | | | | | | | | |
11/9/22 17:00 | 11/7/22 | IDXX | Idexx Laboratories Inc /de | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Mazelsky Jonathan Jay | ME | DO | P,CEO | S.d | -5,060 | 382.49 | 0 | -13 | -18 | 62 | D | | | | | | | | | | | | | | |
11/2/22 16:58 | 10/31/22 | QTNT | Quotient Ltd | Y9 | Health | Diagn | In Vitro & In Vivo Diagnostic | Perceptive Advisors LLC | NY | T | | S | -660 | 0.0800 | 0 | -8,256 | -51 | 7,945 | I | | | | | | | | | | | | | | |
10/20/22 16:30 | 10/18/22 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Montagut Etienne | MA | O | Chief Bu | S.m | -425 | 72.50 | 0 | -6 | -7 | 79 | D | | | | | | | | | | | | | | |
10/20/22 16:30 | 10/18/22 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Marshall Robert J. Jr. | MA | O | CFO,Trea | S | -354 | 73.41 | 0 | -5 | -4 | 126 | D | | | | | | | | | | | | | | |
10/19/22 16:30 | 10/17/22 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S | -27 | 70.50 | 0 | 0 | -1 | 62 | D | | | | | | | | | | | | | | |
9/22/22 17:13 | 9/20/22 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Allen Anthony Joseph | CA | O | Chief Op | S | -24 | 1.39 | 0 | -17 | -8 | 184 | D | | | | | | | | | | | | | | |
9/20/22 17:30 | 9/18/22 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | George Dan | CA | O | CFO,Trea | S | 0 | 1.38 | 0 | 0 | -1 | 46 | D | | | | | | | | | | | | | | |
9/19/22 16:30 | 9/15/22 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S | -33 | 85.83 | 0 | 0 | -1 | 62 | D | | | | | | | | | | | | | | |
9/12/22 16:30 | 9/8/22 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Markison Brian A | MA | D | | S.d | -3,522 | 84.24 | 0 | -42 | -56 | 33 | D | | | | | | | | | | | | | | |
9/8/22 16:30 | 9/6/22 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | McHugh Julie | MA | D | | S | -338 | 78.50 | 0 | -4 | -14 | 26 | D | | | | | | | | | | | | | | |
9/8/22 16:30 | 9/6/22 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Markison Brian A | MA | D | | S.d | -133 | 78.50 | 0 | -2 | -3 | 50 | D | | | | | | | | | | | | | | |
9/6/22 20:48 | 9/1/22 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Mitra Debkishore | CA | DO | CTO | S | 0 | 1.69 | 0 | 0 | 0 | 382 | D | | | | | | | | | | | | | | |
8/29/22 20:22 | 8/27/22 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Collins Kevin Walter | CA | O | Chief Re | S | -15 | 1.72 | 0 | -9 | -2 | 356 | D | | | | | | | | | | | | | | |
8/29/22 20:19 | 8/25/22 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Kashmolah Ghazi | CA | O | Ex VP,Ch | S | -3 | 1.93 | 0 | -2 | -1 | 185 | D | | | | | | | | | | | | | | |
8/24/22 15:54 | 8/17/22 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Kashmolah Ghazi | CA | O | Ex VP,Ch | S.a | -48 | 2.52 | 0 | -19 | -10 | 181 | D | | | | | | | | | | | | | | |
8/22/22 16:30 | 8/18/22 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Blanchfield Paul | MA | O | COO | S | -125 | 83.39 | 0 | -2 | -2 | 76 | D | | | | | | | | | | | | | | |
8/19/22 21:40 | 8/17/22 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Kashmolah Ghazi | CA | O | Ex VP,Ch | S.m | -62 | 2.74 | 0 | -23 | -11 | 177 | D | | | | | | | | | | | | | | |
8/19/22 16:06 | 8/17/22 | CLDX | Celldex Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Cavanaugh Sarah | NJ | O | SVP of C | S.dm | -1,200 | 36.72 | 0 | -33 | -96 | 1 | D | | | | | | | | | | | | | | |
8/19/22 16:05 | 8/17/22 | CLDX | Celldex Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Young Diane C. | NJ | O | SVP,Chie | S.d | -709 | 37.30 | 0 | -19 | -29 | 47 | D | | | | | | | | | | | | | | |
8/17/22 19:43 | 8/15/22 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Sabens Andrea | MA | O | Chief Ac | S | -32 | 82.82 | 0 | 0 | -1 | 63 | D | | | | | | | | | | | | | | |
8/17/22 19:42 | 8/15/22 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Marshall Robert J. Jr. | MA | O | CFO,Trea | S | -414 | 82.82 | 0 | -5 | -4 | 131 | D | | | | | | | | | | | | | | |
8/17/22 16:06 | 8/15/22 | CLDX | Celldex Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Marucci Anthony S | NJ | DO | P,CEO | S.d | -4,520 | 37.66 | 0 | -120 | -81 | 28 | D | | | | | | | | | | | | | | |
8/17/22 16:05 | 8/15/22 | CLDX | Celldex Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Wright Richard M. | NJ | O | SVP,CCO | S.d | -578 | 37.71 | 0 | -15 | -99 | 0 | D | | | | | | | | | | | | | | |
8/15/22 17:03 | 8/11/22 | LNTH | Lantheus Holdings, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Niedzwiecki Daniel | MA | O | See Rema | S | -248 | 82.66 | 0 | -3 | -4 | 68 | D | | | | | | | | | | | | | | |